Carclo. Contract delays to affect H218 performance. Delayed placement of contracts by customers. Non-medical demand lower than forecast.

Similar documents
Carclo. All going to plan. TP benefiting from expansion to support customers. FLTC acquisition supports further Wipac growth

TXT e-solutions. Strong cash flow supports dividend boost. PACE acquisition boosts FY16 performance. Minor changes to earnings forecasts

Carr s Group. Diversification continues to give resilience. PBT up for H117 as UK farmers gain in confidence

Eddie Stobart Logistics

JackpotJoy plc. A transformational year. Revenue and EBITDA slightly ahead of estimates. Strong operating cash flow dividends from 2019

Paysafe Group. Growth normalises. Growth moderates in H117. Pro forma financials show potential impact of deals

GB Group. PCA acquisition an excellent fit. PCA adds SME reach to address intelligence services. Earnings enhancing despite growth investment

Centrale del Latte d'italia

TXT e-solutions. Steady growth in Q3. Growth for both businesses in Q3. Outlook and changes to forecasts

XP Power. Strong demand drives record performance in H1. H118 sees continuation of strong growth

TerraNet Holding. Irons in the fire. Five new strategic development orders won in Q317. Cash flow burn reflecting multi-project activity

Evolva. EverSweet. Delivering on the new strategy. FY17 results. Valuation: Fair value of CHF0.60 per share. FY17 results.

International Stem Cell

Centrale del Latte d'italia

ReNeuron Group. US exclusivity deal - more than non-dilutive cash. FY18 results: Strong cash balance. Funded for a busy programme

Shanks Group. Global commodity crisis offsetting progress. Netherlands Commercial progress encouraging

KEFI Minerals. Counting down to production. Outstanding matters. Valuation: 6.55p/sh in FY18 rising to 7.21p/sh in FY19.

K3 Business Technology

Piteco. Bold entry into the US marketplace. Acquisition of US payments software provider. Forecasts: FY18 revenues rise by 34%, EPS by 12%

K3 Business Technology

Quixant. A very promising year ahead. Volume deliveries to new major customers. Current order book over double the prior year

Regional REIT. Asset growth and refinancing completed. Further portfolio growth and diversification. Acquisition benefit offset by underlying revision

Mondo TV. YooHoo! Netflix deal drives significant upgrades. Global deal with Netflix, new Chinese productions. Significant increase to five-year plan

GFT Group. IT services pure-play focused on banks. Disposal of emagine. Acquisition of Adesis Netlife SL. Forecasts: Adjusted for effects of the deals

artnet For art's sake FY15: Art fair partnerships and forays to China Intended reporting change Valuation: Overshadowed Q1 figures

Regional REIT. Retail eligible bond 4.5% Regional markets have remained robust. Retail eligible bond offering. Launch of bond issue.

Sealegs Corporation. Sea change. H1 update. Changing business mix. Valuation: New focus improves valuation. H1 results

Circle Property. Lifting estimates again. Revaluation gains and strong rent growth. Upside potential from refurbished assets

OTC Markets Group. Record quarterly revenues. Q115 Corporate services revenue rises 54% Operating expenses rise 18% in Q115.

Carr's Group. Profits dip as expected with FY18 recovery underway. FY17 impacted by external factors. FY18 recovery underway

Ubisense. Geographic expansion. Ubisense acquires Asian partner. Expanding the opportunity in Asia. Changes to forecasts

Medserv. Pieces fitting into place H118. On track to deliver growth. Valuation: Backlog underpins uplift. H118 results. Industrial support services

Monitise. FY14 growth on track. Focus on expanding the network. Guidance maintained for FY14. Valuation: Reflects growth potential.

The Quarto Group. Good visibility into H2. Building on strengths. Group in improving shape for CFO transition. Valuation: Discount remains substantial

LPE sector performance

Antofagasta. Q3 production and costs better than forecast. Q313 production ahead of forecast. FY13 EPS forecast upgraded

Helma Eigenheimbau. Scale research report - Update. Market bottlenecks limiting momentum. H117 results showing moderate growth

Progress in a backward market

Gear4music Holdings. Market share gains and margin boost. Strong pre-christmas trading. FY18 forecast maintained

Centrale del Latte d'italia

paragon Accelerating progress Q2 displays accelerating performance Guidance changes reflect growth initiatives Valuation: Rating not reflecting growth

GLG Life Tech. Luo Han Guo drives revenue growth. Tate & Lyle LHG contract boosts top line. H3 and H4 leaf should improve stevia margins

Tourism Holdings. ROCE exceeds 14% long-term target. Key drivers remain positive. Deeper customer relationships to drive yield

Polypipe Group. Strong Residential performance. Sector themes maintained, some portfolio tweaks. French disposal modestly dilutive to earnings

Kongsberg Automotive investment headwind, but technology wins results affected by investment, but progress

Cooks Global Foods. Focused on capital requirements results restated. CGF budgets for 650 stores, targets 800 by 2021

Ceres Power Holdings. Progressing towards commercialisation. Progressing the technology. Securing routes to market

Avalon Rare Metals. Refining Nechalacho s future. Nechalacho changing shape significantly. Agreement with Northwest Territory Métis Nation

Expert System. Building the foundations for growth. Contract wins delayed by integration efforts. Company confident that outlook remains positive

WANdisco. Cloud OEM agreement with Virtustream/Dell. Second OEM, first for cloud. Cloud credentials strengthened

China Water Affairs Group

Mondo TV. Guidance raised for full year. H117 highlights: Strong licensing sales. Outlook: Net profit guidance raised

Vectron Systems. Scale research report - Update. Evolving the business. Boost from regulatory changes recedes. Increased focus on cloud services

Pura Vida Energy. Reaction to drilling. Sharp sell-off on no news. Results expected no earlier than late July. Increased stock volatility not unusual

TransContainer. Russian rail volumes continue to grow. Story intact: Runaway market growth. EBITDA growth set to continue

Aberdeen Asset Management

Global Bioenergies. String of successes and new financing. Forecasts updated to reflect results & new financing

Record. Maintaining client commitment. FY18 result. Outlook: Seeing well-diversified interest. Valuation. FY18 results. Financial services

SNP Schneider-Neureither & Partner

ADVA Optical Networking FY12 results

Cooks Global Foods. Funded for growth. Growth plans. Interim results. Valuation: Upside in valuation. Interim results.

Oceania Natural. NXT Company Spotlight. Preliminary results and delisting proposal. Preliminary results at March 2018: Increased loss

InMed Pharmaceuticals

Evolva. A cloudier picture. Production update agreement not yet reached. FY16 revenue lower than previously expected

Ceres Power Holdings. Strengthening customer engagement. Customer engagement intensifying. Engagement underpinned by technology advances

SITO Mobile. A strong end to a transformational year. Transformational year ends on a high note. Pipeline looks promising

Sigma Capital Group. New funding structure to finance project growth. JV to deliver initial 200m portfolio of 2,000 homes.

S&U. Positioning for sustainable growth. H119 results. Adapting to market background. Valuation: Maintained on slightly lower estimates.

Entertainment One. PJ Masks catching Peppa. Strong growth in profitability. PJ Masks joins Peppa as a global Family brand

Rockhopper Exploration

Vislink. Conditional sale of hardware division. Industry evolution affected VCS performance. Group expected to return to profitability in FY17

Athersys. Progress on all fronts. Timeline for FDA approval accelerated. mrs shift analysis is primary endpoint. Moving forward in Japan

NAHL Group. Maiden interims show strong profit growth. Significant rise in margins in H114. FY14e and FY15e PBT and EPS estimates raised

Bionomics. PTSD programme on track for results in Q3. PTSD treatment complete, results coming. Agitation study ongoing

Caledonia Mining. Production in line, EPS down on macro factors. Record quarterly production. New (lower) gold price forecasts

High-impact exploration offshore Philippines

Game Digital. Not a game changer. Early days in the strategic transition. Trading update: Short-term timing delays

Thin Film Electronics

Boku. Strong H1 supports future growth. Strong volume growth continues in H118. Investing for sustained growth. Valuation: Premium for growth

Expert System. Turning the AI hype into reality. Pace of new business accelerated in H2. Increasing interest in commercial application of AI

Intec Pharma. Phase III more than half the way there. Gastroscopy substudy complete. New pharmacokinetic study on deck. New plan for AP cannabinoids

AFH Financial Group. Delivering on acquisitions and organic growth. FY15 results: Beating expectations on organic growth

The Quarto Group. 40 years young. Children s list delivers on promise. Investing in new titles, building IP for future sales

Park Group. Continued growth in earnings and cash. Small forecast increase, awaiting IFRS 15. New management team takes up the baton

K3 Business Technology Update on preliminary results

aap Implantate AG Biomaterials for sale as LOQTEQ growth takes off Robust growth driven by LOQTEQ in FY14 Sale of Biomaterials under review

Tungsten Corporation. Focusing on growth and efficiency. AGM update. Outlook. Valuation. Company update. Financial services

Mercia Technologies. Good progress across the portfolio. 17.7% growth in direct investment portfolio. Commercial traction in key companies

Pantaflix. Scale research report Update. Name change reflects VOD strategy. Progressing its VOD strategy. Overview of H117 results

Angel Mining. Update. Investment summary: First gold. Price 7.25p Market Cap 22m. Future developments at Nalunaq

DeA Capital. Expanding asset management platform. AUM growth accelerates in Q4. A healthy net investment balance supports dividends

Intelligent Energy Holdings

PPHE Hotel Group. More of the same. Continued outperformance. Favourable asset management climate. Valuation: Closing the discount to NAV

Pan African Resources

German Startups Group

TransGlobe Energy. EGPC receivables issue resolved. EGPC makes significant receivables reduction. Focus in Egypt shifts from seismic to drilling

Photocure. Nordic sales bounce back. Eight more blue light cystoscopy units placed in US. Hexvix/Cysview added to bladder cancer guidelines

PDL BioPharma. An update on several fronts. Valeant has not been reporting or paying on time. Auvi-Q recalled, but there is an interest reserve

Bellus Health. Thallion deal likely as Jaguar backs revised CVRs. CVR revisions mostly modest; Jaguar supports bid

Crossject. A reinforced cash position. Zeneo Midazolam targets under-served market. Pipeline expected to progress in 2017

Transcription:

Carclo Contract delays to affect H218 performance Trading update Tech hardware & equipment Carclo has recently announced that its FY18 performance is likely to be lower than previously expected. This is because of contract delays affecting both the Technical Plastics (CTP) and LED Technologies (LED) divisions as well as a delay to the anticipated ramp-up in a non-medical project for CTP, which management expected would benefit H218. We reduce our FY18 and FY19 estimates, introduce FY20 estimates and revise our indicative valuation range from 177-187p/share to 145-154p/share. 22 January 2018 Price 83.0p Market cap 61m Net debt ( m) at end September 2017 29.6 Shares in issue 73.3m Free float 91.7% Year end Revenue ( m) PBT* ( m) EPS* (p) DPS (p) P/E (x) Yield (%) 03/16 119.0 8.8 10.1 0.9 8.2 1.1 03/17 138.3 11.0 12.1 0.0 6.9 N/A 03/18e 140.6 8.9 9.2 0.0 9.0 N/A 03/19e 147.7 11.0 11.2 3.9 7.4 4.7 Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Code Primary exchange Secondary exchange Share price performance CAR LSE N/A Delayed placement of contracts by customers The operational issues affecting the CTP division that were noted at the interim stage have been addressed. However, the division continues to be affected by contract delays, specifically the award of two large tooling and automation projects. Management is seeking to reduce reliance on winning new tooling and automation contracts by improving underlying operating margins from existing business. In our November update, we noted that LED divisional growth was dependent on continuing to secure new projects. The award of three new contracts has been delayed due to customers changing their time horizons on vehicle launches. Management is confident that Wipac will be successful in winning a number of these programmes, but the delays will have an impact on divisional FY18 performance. Despite this setback, the group s LED supercar lighting business has performed as anticipated and new product launches continue to be made on time. Non-medical demand lower than forecast In addition, management had expected an improvement in CTP performance during H218 because a large and longstanding non-medical customer had been indicating a ramp up in demand for moulded components during the period. This has not yet happened. Noting the variability in demand for non-medical projects, which contributed to H118 underperformance as well, management continues to increase the proportion of medical related work, upgrading capabilities at the Czech site so it can take on medical projects. Valuation We use a P/E-based, sum-of-the-parts methodology with three sets of sample peers drawn from the medical device manufacturing (P/E of 18.0x), automotive (mean P/E of 18.9x) and aerospace (mean P/E 21.3x) sectors to reflect the diversity of Carclo s operations. This gives an indicative valuation range of 145-154p per share (previously 177-187p). Newsflow regarding receipt of contract awards should be supportive of the stock, helping to close the valuation gap. % 1m 3m 12m Abs (34.5) (38.5) (39.9) Rel (local) (36.0) (40.2) (44.6) 52-week high/low 179.0p 80.0p Business description Carclo is a specialist in high-precision plastic moulding principally in healthcare, optical and automotive applications. Its two main end-markets are high-volume medical consumables and lowvolume, very high-value automotive lighting, typically for supercars. Next events Prelims June 2018 Analysts Anne Margaret Crow +44 (0)20 3077 5700 Dan Ridsdale +44 (0)20 3077 5729 tech@edisongroup.com Edison profile page Carclo is a research client of Edison Investment Research Limited

Changes to estimates We have revised our estimates to reflect lower than previously expected revenues and profits in both the larger divisions, CTP and LED Technologies, as well as smaller downwards revisions for the smaller Aerospace division as it continues to shift to lower-value precision machining work. We introduce FY20 estimates, taking a conservative view on the impact of deliveries for the first mid-volume lighting programme, which are expected to commence during the year. Carclo is likely to benefit from cuts in US corporation tax. However, we are not making any changes to our underlying tax rate (modelled at 25% for FY18, 26% for FY19 and 27% for FY20) until management has evaluated the details of the changes. Exhibit 1: Revisions to estimates Year end 31 March FY17 FY18e FY19e FY20e Actual Old New % change Old New %change New Group revenues ( m) 138.3 152.2 140.6-7.6% 165.5 147.7-10.8% 157.8 Group adjusted PBT ( m) 11.0 12.5 8.9-28.5% 15.0 11.0-26.3% 12.1 Group adjusted EPS (p) 12.1 12.9 9.2-28.5% 15.2 11.2-26.3% 12.1 Group DPS (p) 0.0 0.0 0.0 0.0% 3.9 3.9 0.0% 4.2 Source: Carclo, Edison Investment Research Board changes Group Finance Director Robert Brooksbank is leaving the group on 31 March 2018 after 14 years in his current role. The board has begun the process of recruiting his replacement. Richard Ottaway, group financial controller and company secretary, will act as the interim chief financial officer from 1 April 2018 until a permanent successor is appointed. In addition, Non-executive Chairman Michael Derbyshire will retire from the board at the AGM in July 2018, having served over 12 years as a non-executive director, almost six years of which has been spent as chairman. Michael will be succeeded by Mark Rollins, who joined the board as non-executive director on 1 January 2018. Mark is currently also senior non-executive director of Tyman and Vitec and non-executive chairman of Sigma Precision Components UK. He was group chief executive of Senior from March 2008 to June 2015, having previously served as group FD of Morgan Crucible from July 2000. Valuation Examination of the comparators shows that Carclo, which has a diversified business model, is trading on multiples that are substantially lower than those for medical device companies and below those for automotive and aerospace industries. We use a sum-of-the-parts approach to determine an indicative FY18e P/E multiple for Carclo, as this methodology acknowledges that around half of its divisional operating profit is attributable to the sale of products to the global healthcare industry. Where available, the P/E multiple applied to each division is the mean for each sector, as shown in Exhibit 2. There are a number of companies manufacturing high-volume medical products but the key one of relevance, which we use in the sum-of-the-parts calculation, is Gerresheimer, as its products are primarily for use in medical/pharmaceutical test facilities, rather than for patient care (Ambu, Coloplast and Straumann). As can be seen from Exhibit 2, the latter trade on much higher multiples and are excluded from our sum-of-the-parts calculations. As shown in Exhibit 3, the weighted average P/E multiple derived from the multiples for the three sectors is 18.6x. Carclo 22 January 2018 2

Exhibit 2: Listed peers Name Market cap EV/sales EV/sales EV/EBITDA EV/EBITDA P/E 1FY (x) P/E 2FY (x) ($m) 1FY (x) 2FY (x) 1FY (x) 2FY (x) CARCLO @ 81.6p (current share price) 82 0.6 0.6 5.4 4.6 8.9 7.3 CARCLO @ 145p 147 0.9 0.9 8.4 7.1 15.8 13.0 CARCLO @ 154p 156 1.0 0.9 8.8 7.5 16.7 13.7 Healthcare: patient implants and disposables AMBU A/S-B 4,414 10.3 8.9 40.5 31.3 66.8 50.2 COLOPLAST-B 18,067 6.7 6.2 19.0 17.7 27.0 25.0 STRAUMANN HOLDING AG-REG 11,490 10.2 8.7 34.6 28.9 45.5 38.0 Healthcare: drug delivery and packaging GERRESHEIMER AG 2,753 2.3 2.2 10.0 9.6 18.0 16.4 Automotive AMERICAN AXLE & MFG HOLDINGS 2,090 0.9 0.8 5.2 4.7 5.3 5.6 BORGWARNER INC 12,066 1.5 1.4 8.6 8.1 15.0 13.6 BREMBO SPA 5,435 1.9 1.8 9.8 9.2 16.0 16.3 DELPHI TECHNOLOGIES PLC 5,268 1.3 1.2 7.0 6.6 13.4 12.5 FAURECIA 12,000 0.6 0.5 5.6 5.2 16.0 14.1 HALDEX AB 497 0.9 0.9 10.7 8.0 21.7 18.6 HELLA GMBH & CO KGAA 7,709 0.9 0.9 6.7 6.1 15.8 14.5 LEONI AG 2,551 0.5 0.5 6.9 6.5 14.9 13.8 MAGNA INTERNATIONAL INC 21,431 0.6 0.6 6.0 5.7 10.0 8.9 PARAGON AG 450 3.2 2.6 19.5 15.0 61.1 39.9 VALEO SA 18,951 0.9 0.8 7.0 6.1 15.2 13.3 VISTEON CORP 4,293 1.3 1.2 11.0 10.1 22.0 19.4 Mean 1.2 1.1 8.7 7.6 18.9 15.9 Aerospace FACC AG 1,061 1.4 1.3 12.2 10.5 24.0 19.2 LATECOERE 668 0.8 0.8 10.9 10.7 17.2 15.1 SENIOR PLC 1,700 1.4 1.3 11.2 10.2 21.1 19.2 TT ELECTRONICS PLC 526 1.3 1.2 11.5 11.5 22.8 20.1 Mean 1.2 1.2 11.5 10.7 21.3 18.4 Source: Bloomberg, Edison Investment Research. Note: Prices at 15 January 2018. Applying the weighted average P/E multiple of 18.6x to Carclo s FY18e (to March 2018) EPS of 9.2p gives an indicative valuation of 170.8p/share. We think that Carclo s relatively small market capitalisation compared to the majority of peers merits some discount to this. The share price has dropped by over 30% since the recent trading update. We believe that the discount of over 100% to our indicative valuation of 170.8p implied by the share price following this fall is far too severe given the stability provided by long-term customer relationships combined with potential for growth in Carclo s two main divisions. Applying an arbitrary 10-15% discount (which is consistent with our previous treatment) gives a valuation range of 145-154p (see Exhibit 3). Our valuation range was previously 177-187p. To cross-check our valuation, we compare EV/EBITDA multiples implied by our P/E-derived values with a blended sum-of-the-parts EV/EBITDA for the peer group. Our indicative valuation of 145-154p implies a year one EV/EBITDA range of 8.4-8.8x (see Exhibit 2), which is close to the peer group blended year one EV/EBITDA multiple of 9.5x. Exhibit 3: SOTP calculation Division % FY18e EBIT P/E % FY18e EBIT EV/EBITDA CTP 46.9% 18.0x 46.9% 10.0x LED 47.9% 18.9x 47.9% 8.7x Aerospace 5.2% 21.3x 5.2% 11.5x Weighted average P/E 18.6x 9.5x FY18e EPS 9.2p Undiscounted indicative value 170.8p Indicative value applying 10% discount 153.7p Indicative value applying 15% discount 145.2p Source: Edison Investment Research Carclo s share price has dropped by over 30% following the trading update. We believe that newsflow demonstrating that the contract delays besetting both divisions are over should help close Carclo 22 January 2018 3

Exhibit 4: Financial summary the valuation gap, with potential for further share price appreciation beyond this as Carclo begins to deliver on the mid-volume automotive lighting programmes. Year end 31 March 000s 2016 2017 2018e 2019e 2020e IFRS IFRS IFRS IFRS IFRS PROFIT & LOSS Revenue 118,974 138,282 140,631 147,655 157,759 EBITDA 13,840 17,033 15,781 18,532 20,080 Operating Profit (before amort. and except). 10,034 12,498 10,781 13,032 14,080 Intangible Amortisation 0 0 0 0 0 Exceptionals (4,857) (541) 0 0 0 Other 0 0 0 0 0 Operating Profit 5,177 11,957 10,781 13,032 14,080 Net Interest (1,282) (1,479) (1,850) (2,000) (2,000) Profit Before Tax (norm) 8,752 11,019 8,931 11,032 12,080 Profit Before Tax (FRS 3) 3,895 10,478 8,931 11,032 12,080 Tax (1,708) (2,496) (2,233) (2,868) (3,262) Profit After Tax (norm) 6,692 8,418 6,698 8,164 8,819 Profit After Tax (FRS 3) 2,187 7,982 6,698 8,164 8,819 Average Number of Shares Outstanding (m) 66.2 69.4 73.0 73.0 73.0 EPS - normalised (p) 10.1 12.1 9.2 11.2 12.1 EPS - normalised fully diluted (p) 10.1 12.1 9.2 11.2 12.1 EPS - IFRS (p) 3.3 11.5 9.2 11.2 12.1 Dividend per share (p) 0.9 0.0 0.0 3.9 4.2 EBITDA Margin (%) 11.6 12.3 11.2 12.6 12.7 Operating Margin (before GW and except.) (%) 8.4 9.0 7.7 8.8 8.9 BALANCE SHEET Fixed Assets 66,660 80,085 87,885 91,685 94,485 Intangible Assets 20,257 26,323 26,623 26,923 27,223 Tangible Assets 36,597 43,423 50,923 54,423 56,923 Investments 9,806 10,339 10,339 10,339 10,339 Current Assets 59,635 80,187 77,545 83,096 86,876 Stocks 15,596 19,250 21,962 21,845 22,475 Debtors 26,647 38,468 40,070 40,858 41,061 Cash 16,692 22,269 15,313 20,194 23,140 Other 700 200 200 200 200 Current Liabilities (33,428) (46,884) (45,444) (46,982) (47,939) Creditors (22,732) (27,996) (26,556) (28,094) (29,051) Short term borrowings (10,696) (18,888) (18,888) (18,888) (18,888) Long Term Liabilities (60,000) (69,125) (69,125) (69,125) (69,125) Long term borrowings (30,746) (29,406) (29,406) (29,406) (29,406) Other long term liabilities (29,254) (39,719) (39,719) (39,719) (39,719) Net Assets 32,867 44,263 50,861 58,675 64,296 CASH FLOW Operating Cash Flow 13,933 8,916 9,027 18,398 19,205 Net Interest (861) (762) (750) (900) (900) Tax (1,253) (2,086) (2,233) (2,868) (3,262) Capex (9,593) (7,683) (13,000) (9,500) (9,000) Acquisitions/disposals 0 (5,672) 0 (250) (250) Financing 20 7,616 0 0 0 Dividends (1,821) (596) 0 0 (2,847) Net Cash Flow 425 (267) (6,956) 4,880 2,946 Opening net debt/(cash) 24,518 24,750 26,025 32,981 28,100 HP finance leases initiated 0 0 0 0 0 Other (657) (1,008) 0 0 0 Closing net debt/(cash) 24,750 26,025 32,981 28,100 25,154 Source: Carclo accounts, Edison Investment Research Carclo 22 January 2018 4

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Carclo and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are wholesale clients for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a personalised service and, to the extent that it contains any financial advice, is intended only as a class service provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ( FTSE ) FTSE 2018. FTSE is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE s express written consent. Frankfurt +49 (0)69 78 8076 960 Carclo Schumannstrasse 2234b January 2018 280 High Holborn 295 Madison Avenue, 18th Floor Level 12, Office 1205 5 60325 Frankfurt Germany London +44 (0)20 3077 5700 London, WC1V 7EE United Kingdom New York +1 646 653 7026 10017, New York US Sydney +61 (0)2 8249 8342 95 Pitt Street, Sydney NSW 2000, Australia